Biocon gains on launching GLP-1 peptide, Liraglutide in Netherlands

15 Dec 2025 Evaluate

Biocon is currently trading at Rs. 391.30, up by 4.65 points or 1.20% from its previous closing of Rs. 386.65 on the BSE.

The scrip opened at Rs. 387.45 and has touched a high and low of Rs. 391.40 and Rs. 383.70 respectively. So far 60966 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.

Last one week high and low of the scrip stood at Rs. 395.50 and Rs. 375.90 respectively. The current market cap of the company is Rs. 52021.26 crore.

The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively.

Biocon has launched its GLP-1 peptide, Liraglutide, for diabetes (gVictoza) and obesity (gSaxenda), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

390.55 3.90 (1.01%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×